AUS
NZ
UK
CA
USA
IND
Highlights
Institutional investors have adjusted their holdings in AbbVie, with some funds increasing their positions.
Recent filings indicate that hedge funds and asset management firms hold a significant stake in the company.
AbbVie remains a focal point among large investment firms, with several funds making strategic adjustments.
Institutional Adjustments in AbbVie Holdings
Recent regulatory filings show that institutional investors have made changes to their positions in AbbVie Inc. (NYSE:ABBV). Woodward Diversified Capital LLC adjusted its stake in the company, reporting a 27.5% reduction in its holdings. The fund now holds 6,490 shares after divesting 2,456 shares during the last quarter. Despite this adjustment, AbbVie still accounts for 0.8% of the fund’s total holdings, positioning it as the 24th largest asset in its portfolio.
Other investment firms have also restructured their holdings. State Street Corp increased its position in AbbVie by 1.6% during the third quarter. This adjustment resulted in the firm owning 79,067,935 shares, valued at $15.6 billion at the time. FMR LLC also expanded its stake, adding 511,470 shares, bringing its total holdings to 13,630,404 shares worth $2.69 billion.
Hedge Fund Activity and Strategic Moves
Hedge funds have made notable adjustments to their positions in AbbVie. UBS Asset Management Americas LLC raised its stake by 6.1% in the third quarter, increasing its holdings to 10,175,926 shares. This shift reflects an investment worth approximately $2 billion. Additionally, Massachusetts Financial Services Co. MA adjusted its holdings, boosting its position by 4.2% with the acquisition of 373,802 additional shares, bringing its total to 9,330,779 shares.
International Assets Investment Management LLC made a significant move by increasing its stake in AbbVie by 1,745% in the same period. This firm now holds 4,728,063 shares valued at $933.7 million, demonstrating a substantial adjustment in portfolio allocation.
Broader Institutional Ownership in AbbVie
AbbVie continues to be a major asset among institutional investors. Reports indicate that hedge funds and asset management firms collectively own 70.23% of the company's shares. This high level of institutional ownership underscores the confidence that major investment entities have in the pharmaceutical company's long-term prospects.
While some firms have reduced their exposure, others have expanded their positions, leading to an evolving landscape in AbbVie’s ownership structure. These shifts highlight the ongoing strategic decisions made by large financial entities regarding their stake in the company.
